ArticleAmerican heart journal plus : cardiology research and practice2025
Real-world interventional outcomes for cardiogenic shock complicating acute myocardial infarction.
Article in American heart journal plus : cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cardiogenic shock 2025: Understanding real world outcomes and contemporary practice to help guide improvements in care.American heart journal plus : cardiology research and practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myocardial infarction with cardiogenic shock (AMICS) carries high mortality and remains a major concern. This concern drives use of interventions with marginal benefit and some evidence of harm. The configuration of hospital care and allocation of interventions for AMICS in our health system created a natural experiment to analyze interventional outcomes for patients with AMICS. Objective: To compare clinical outcomes among AMICS patients treated with mechanical circulatory support (MCS) using a micro-axial left ventricular assist device and intra-aortic balloon counter-pulsation (IABP). Design setting participants outcome measures: In this observational study in a large health system, we used clinical registry data augmented with data from other sources to analyze 30-day and 180-day mortality as well as complications including major bleeding, and access site injury. Results: Of 505 patients with AMICS, 73 were treated with MCS and 160 with IABP. Baseline characteristics were similar between treatment groups except infarct location. Multivariable logistic regression showed that MCS was associated with 1.92 (CI = 1.10-3.37) times higher 30-day mortality risk and 2.03 (CI = 1.17-3.57) times higher 180-day mortality risk. In MCS-inclined hospitals as compared with IABP-inclined hospitals, patients had significantly higher 180-day mortality (45.3 % versus 33.9 %, Conclusion: In this real-world setting, MCS use for AMICS was associated with higher complication rates. Before using this device for AMICS, clinicians should consider tight selection criteria to minimize harm and maximize overall benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.